Physician profile
Michael P Macris
NPI 1780753905
$2,067.76
in general payments reported to CMS, 2019-2025
15 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $28.20 · 2021: $8.36 · 2022: $742 · 2023: $188 · 2024: $393 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $897.96 | 2019-2024 | |
| Edwards Lifesciences Corporation | $305.59 | 2019-2024 | |
| Abiomed | $213.00 | 2019-2024 | Impella |
| Getinge USA Sales, LLC | $143.03 | 2020-2022 | |
| Medtronic Vascular, INC. | $131.28 | 2019 | |
| Medtronic, INC. | $92.33 | 2023 | Swiftset |
| Shockwave Medical, INC | $74.85 | 2025 | |
| Bard Peripheral Vascular, INC. | $47.63 | 2019 | |
| Abbott Laboratories | $45.73 | 2024 | Sjm Regent, Epic |
| Terumo Cardiovascular Systems Corporation | $30.76 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $22.92 | 2025 | Zilretta, Exparel, Iovera |
| Livanova USA, INC. | $20.96 | 2019 | |
| Boston Scientific Corporation | $16.80 | 2025 | Watchman Flx |
| Angiodynamics, INC. | $16.56 | 2025 | Angiovac |
| Kls-Martin L.P. | $8.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.